Cefiderokol
Cefiderokol appears to be a misspelling of cefiderocol, a siderophore cephalosporin antibiotic developed by Shionogi and marketed in some regions under the brand name Fetroja. The standard spelling in medical literature is cefiderocol. The following summarizes cefiderocol’s characteristics.
Cefiderocol works by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins. Its distinctive feature
The drug is primarily active against Gram-negative bacteria, including Enterobacterales, Pseudomonas aeruginosa, and certain carbapenem-resistant strains.
Indications and administration: cefiderocol has been approved for adults with complicated urinary tract infections, including pyelonephritis.
Safety and regulatory considerations: clinical trials raised concerns about higher all-cause mortality in some carbapenem-non-susceptible infections